不同β受体阻滞剂治疗婴幼儿血管瘤的疗效观察OA北大核心CSTPCD

Objective To observe the clinical efficacy and complications of β receptor blockers for in-fantile hemangioma(IH)and observe the effect on growth and development during treatment.Methods From January 2017 to may 2022,33 IH children were recruited.They were randomized into two groups of propranolol(n=22)and atenolol(n=11)according to parental wishes.No significant inter-group differences existed in age,gender,location or type(P＞0.05).The former group received an oral dose of non-selective propranolol 1.5-2 mg·kg-1·d-1.And the latter group was prescribed with atenolol at 0.5 mg·kg-1·d-1 in the first week and then 1 mg·kg-1·d-1.During monthly follow-ups,the changes of clinical manifestations such as tumor color,size,texture and the complications were recorded.Color Doppler ultrasound was performed for measuring tumor volume and evaluating growth and development.Results There was nostatistically significant difference in the age,gender,Location,and type of initial diagnosis between the two groups of chidren(P＞0.05).The effective rate of both groups was 100％.No statistically significant reduction occurred in tumor vol-ume in neither groups at Month 1,5-6 and 10-12 post-treatment(P＞0.05).Adverse reactions of drug do-sing occurred in propranolol group(5/22,22.7％)with respiratory symptoms,fretting or sleep disorder and atenolol group(2/11,18.2％)with fretting or sleep disorder.No other serious adverse reactions occurred.No abnormality was found in physical development of neither groups during follow-ups.The developmental quotient of two groups did not differ significantly at Month 1/3/6/9 post-dosing(P＞0.05).Conclusions The effica-cies and complications of propranolol and atenolol are comparable for infantile hemangioma.No significant inter-group difference exists in growth and development during treatment.Regarding the impact of respiratory tract,atenolol may replace propranolol for infantile hemangiomas.